(Q37600964)

21 August 2017

1 reference

title

Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells (English)

1 reference

21 August 2017

1 reference

Andrew J Rech

1

1 reference

PubMed ID

19769742

21 August 2017

Robert H Vonderheide

series ordinal

2

1 reference

PubMed ID

19769742

21 August 2017

language of work or name

English

0 references

publication date

1 September 2009

1 reference

Annals of the New York Academy of Sciences

21 August 2017

1 reference

21 August 2017

1174

1 reference

21 August 2017

99-106

1 reference

Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific

21 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2009.04939.X

Crossref

reference URL

Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2009.04939.X

Crossref

reference URL

10.1111/J.1749-6632.2009.04939.X

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference

PubMed ID

19769742